M. Saladin entrera en fonction le 1er mars 2012 et succédera à Robert Schmid. Ce dernier a décidé de reprendre son poste précédent de directeur des finances de la filiale Acino AG à Miesbach en Allemagne, pour des raisons personnelles, a indiqué la société.
Pendant les dix dernières années, M. Saladin a été CFO et membre de la direction de Mepha. Dans cette fonction, il a été responsable des divisions Controllings, Finances et Comptabilité, Informatique, Management du personnel et juridique du groupe.
Communiqué original :
Acino names new Chief Financial Officer
Acino names Walter Saladin as the Group’s
new Chief Financial Officer and a Member of Group Management effective March 1, 2012. In this function, he is replacing Robert Schmid who, for personal reasons, has decided to return to his previous position as Chief Financial Officer of the subsidiary Acino AG (in Miesbach, Germany).
For the past ten years, Walter Saladin has been Chief Financial Officer and a Member of Management of Mepha AG. In this role he was responsible for controlling, finance and accounting, IT, human resources and legal of the Group. Previously, he held various senior management positions in finance and controlling with industrial companies in Switzerland, and as a consultant and project leader with the Swiss Trust Company AG, Switzerland’s oldest trust business. For additional information please consult his profile under www.acino-pharma.com.
“Walter brings a very broad-based professional expertise to his new assignment. In addition, his in-depth understanding of the Mepha operations will be invaluable to Acino over the forthcoming integration process. We extend a warm welcome to him as a new member of Acino’s leadership team," said Peter Burema, CEO of the Acino Group. He added: “I thank Robert for his important contributions and his high personal dedication to our company. We fully understand his motives for the career change and are very happy to be able to retain him in a key function in our company. I wish Walter and Robert much success and personal satisfaction in their new positions.”
Acino – Delivering Health
Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies. The Acino Group is headquartered in Basle, at present has about 870 employees (including staff members from Mepha) and generated annual revenues of EUR 128 million in 2010.
www.acino-pharma.com
Pendant les dix dernières années, M. Saladin a été CFO et membre de la direction de Mepha. Dans cette fonction, il a été responsable des divisions Controllings, Finances et Comptabilité, Informatique, Management du personnel et juridique du groupe.
Communiqué original :
Acino names new Chief Financial Officer
Acino names Walter Saladin as the Group’s
new Chief Financial Officer and a Member of Group Management effective March 1, 2012. In this function, he is replacing Robert Schmid who, for personal reasons, has decided to return to his previous position as Chief Financial Officer of the subsidiary Acino AG (in Miesbach, Germany).
For the past ten years, Walter Saladin has been Chief Financial Officer and a Member of Management of Mepha AG. In this role he was responsible for controlling, finance and accounting, IT, human resources and legal of the Group. Previously, he held various senior management positions in finance and controlling with industrial companies in Switzerland, and as a consultant and project leader with the Swiss Trust Company AG, Switzerland’s oldest trust business. For additional information please consult his profile under www.acino-pharma.com.
“Walter brings a very broad-based professional expertise to his new assignment. In addition, his in-depth understanding of the Mepha operations will be invaluable to Acino over the forthcoming integration process. We extend a warm welcome to him as a new member of Acino’s leadership team," said Peter Burema, CEO of the Acino Group. He added: “I thank Robert for his important contributions and his high personal dedication to our company. We fully understand his motives for the career change and are very happy to be able to retain him in a key function in our company. I wish Walter and Robert much success and personal satisfaction in their new positions.”
Acino – Delivering Health
Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies. The Acino Group is headquartered in Basle, at present has about 870 employees (including staff members from Mepha) and generated annual revenues of EUR 128 million in 2010.
www.acino-pharma.com